Results 21 to 30 of about 3,031 (144)

The outcome of the sofosbuvir Based Therapy in the treatment of Hepatitis C Virus Genotype 4 in Egyptian patients [PDF]

African Journal of Gastroenterology and Hepatology, 2019
Background and aim There have been significant advancements during the last few years, with large numbers of ongoing trials with various direct-acting antivirals (DAA) showing high potency against the hepatitis C virus (HCV).
Waleed Ismail, Amr Hanafy, Mohammed Abdelsattar   +2 more
doaj   +1 more source

An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1). [PDF]

PLoS ONE, 2016
Shortening duration of peginterferon-based HCV treatment reduces associated burden for patients. Primary objectives of this study were to assess the efficacy against the minimally acceptable response rate 12 weeks post-treatment (SVR12) and safety of ...
Tarik Asselah, Christophe Moreno, Christoph Sarrazin, Michael Gschwantler, Graham R Foster, Antonio Craxí, Peter Buggisch, Robert Ryan, Oliver Lenz, Jane Scott, Gino Van Dooren, Isabelle Lonjon-Domanec, Michael Schlag, Maria Buti   +13 more
doaj   +1 more source

Safety and efficacy of combination therapy (Simeprevir/Sofosbuvir) in the treatment of chronic HCV genotype IV patients

Medicine Science, 2018
Chronic infection with HCV is a worldwide health problem that may lead to cirrhosis, portal hypertension, hepatocellular failure and hepatocellular carcinoma in most of cases.
Engy A. Wahsh, Amal K. Hussein, Ahmed A. Gomaa, Mohamed A. Baraka, Mohie Al-deen Abead   +4 more
doaj   +1 more source

Computer-aided identification of a series of novel ligands showing high potency as hepatitis C virus NS3/4A protease inhibitors

Bulletin of the National Research Centre, 2021
Background Hepatitis C virus (HCV) is a global medical condition that causes several life-threatening chronic diseases in the liver. The conventional interferon-free treatment regimens are currently in use by a blend of direct-acting antiviral agents ...
Stephen Ejeh, Adamu Uzairu, Gideon Adamu Shallangwa, Stephen E. Abechi   +3 more
doaj   +1 more source

Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort

BMC Infectious Diseases, 2019
Background Although real-life results of sofosbuvir/simeprevir have been extensively reported from the United States, data from other geographical areas are limited. In the French observational cohort, ANRS CO22 HEPATHER, 9432 patients were given the new
Anne Laurain, Sophie Metivier, Georges Haour, Dominique Larrey, Céline Dorival, Christophe Hezode, Fabien Zoulim, Patrick Marcellin, Marc Bourliere, Jean-Pierre Zarski, Dominique Thabut, Laurent Alric, Nathalie Ganne-Carrie, Paul Cales, Jean-Pierre Bronowicki, Ghassan Riachi, Claire Geist, Xavier Causse, Armand Abergel, Olivier Chazouilleres, Philippe Mathurin, Dominique Guyader, Didier Samuel, Albert Tran, Véronique Loustaud-Ratti, Ventzislava Petrov-Sanchez, Alpha Diallo, Clovis Luzivika-Nzinga, Hélène Fontaine, Fabrice Carrat, Stanislas Pol, on behalf of the ANRS/AFEF HEPATHER study group   +31 more
doaj   +1 more source

Simeprevir restores the anti-Staphylococcus activity of polymyxins

AMB Express, 2023
Methicillin-resistant Staphylococcus aureus (MRSA) infection poses a severe threat to global public health due to its high mortality. Currently, polymyxins are mainly used for the treatment of Gram-negative bacterial-related infection, while exhibiting ...
Yuan Wu, Pingyun Wu, Ruolan Wu, Huilong Li, Yao Duan, Chaoni Cai, Zixin Liu, Pengfei She, Di Zhang   +8 more
doaj   +1 more source

New treatments for genotype 1 chronic hepatitis C – focus on simeprevir

Therapeutics and Clinical Risk Management, 2014
Tatsuo Kanda, Shingo Nakamoto, Shuang Wu, Osamu Yokosuka Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan Abstract: Chronic hepatitis C virus (HCV) infection causes end-stage liver diseases and ...
Kanda T, Nakamoto S, Wu S, Yokosuka O
doaj  

The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients

Gut and Liver, 2018
Background/AimsAlthough daclatasvir with asunaprevir was approved in Japan for interferon ineligible or intolerant patients, patients aged ≥75 years were excluded in the phase III trial. The present study aimed to evaluate the safety and efficacy of this
Shinya Taki, Hideyuki Tamai, Yoshiyuki Ida, Naoki Shingaki, Akira Kawashima, Ryo Shimizu, Kosaku Moribata, Takao Maekita, Mikitaka Iguchi, Jun Kato, Taisei Nakao, Masayuki Kitano   +11 more
doaj   +1 more source

Simeprevir for the treatment of hepatitis C virus infection

Pharmacogenomics and Personalized Medicine, 2014
Laure Izquierdo,1 François Helle,1 Catherine François,1,2 Sandrine Castelain,1,2 Gilles Duverlie,1,2 Etienne Brochot1,2 1Virology Research Unit, Jules Verne University of Picardie, 2Department of Virology, Amiens University Hospital, Amiens,
Izquierdo L, Helle F, François C, Castelain S, Duverlie G, Brochot E   +5 more
doaj  

A prospective study in hepatitis C virus treatment-naïve patients showing rheumatologic extra-hepatic manifestations of hepatitis C with associated risk factors: efficacy and safety using sofosbuvir-based direct antiviral therapy

Egyptian Rheumatology and Rehabilitation, 2020
Background To study the most common rheumatologic manifestations of hepatitis C viral (HCV) infection in Egyptian patients and associated risk factors with assessment the effect of current therapies on these manifestations.
Hanan M. Fathi, Wafaa Y. Abdel Wahed, Ahmad A. Gomaa, Essam A. Hassan, Hanaa M. Eid, Fadwa Abdel Reheem, Soha H. Senara   +6 more
doaj   +1 more source